Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul;18(3):1445-1457.
doi: 10.1007/s13311-021-01123-5. Epub 2021 Sep 30.

Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies

Dylan C Brock #  1   2 , Scott Demarest  3   4 , Tim A Benke  3   5   4
Affiliations
Review

Clinical Trial Design for Disease-Modifying Therapies for Genetic Epilepsies

Dylan C Brock et al. Neurotherapeutics. 2021 Jul.

Abstract

Although trials with anti-seizure medications (ASMs) have not shown clear anti-epileptogenic or disease-modifying activity in humans to date, rapid advancements in genomic technology and emerging gene-mediated and gene replacement options offer hope for the successful development of disease-modifying therapies (DMTs) for genetic epilepsies. In fact, more than 26 potential DMTs are in various stages of preclinical and/or clinical development for genetic syndromes associated with epilepsy. The scope of disease-modification includes but is not limited to effects on the underlying pathophysiology, the condition's natural history, epilepsy severity, developmental achievement, function, behavior, sleep, and quality of life. While conventional regulatory clinical trials for epilepsy therapeutics have historically focused on seizure reduction, similarly designed trials may prove ill-equipped to identify these broader disease-modifying benefits. As we look forward to this pipeline of DMTs, focused consideration should be given to the challenges they pose to conventional clinical trial designs for epilepsy therapeutics. Just as DMTs promise to fundamentally alter how we approach the care of patients with genetic epilepsy syndromes, DMTs likewise challenge how we traditionally construct and measure the success of clinical trials. In the following, we briefly review the historical and preclinical frameworks for DMT development for genetic epilepsies and explore the many novel challenges posed for such trials, including the choice of suitable outcome measures, trial structure, timing and duration of treatment, feasible follow-up period, varying safety profile, and ethical concerns.

Keywords: Clinical trial design; Developmental and epileptic encephalopathies; Disease-modifying therapy; Genetic epilepsies; Precision medicine; Rare disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Stepped-wedge trial design structure compared to conventional, parallel RCT with open-label extension
See this image and copyright information in PMC

References

    1. French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia. 2010;51(10):1936–1943. - PubMed
    1. Eun SH, Kim HD, Eun BL, Lee IK, Chung HJ, Kim JS, et al. Comparative trial of low- and high-dose zonisamide as monotherapy for childhood epilepsy. Seizure. 2011;20(7):558–563. - PubMed
    1. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47(7):1094–1120. - PubMed
    1. Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia. 2011;52(4):657–678. - PubMed
    1. Sheridan P. Summary Review: Parampanel Aapproval for the treatment of partial onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age or older. In: FDA, editor. 2018.

Publication types

Substances